Home / Resource Library / Long-term survival benefit of anti-PD-1 therapy in patients with relapsed or refractory classical Hodgkin lymphomaLong-term survival benefit of anti-PD-1 therapy in patients with relapsed or refractory classical Hodgkin lymphoma